Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment-Reference-Cited by-同舟云学术

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment

Published:2019-08-22 Issue:13 Volume:8 Page:5959-5968
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Marks David I.¹,Oostrum Ilse²^ORCID,Mueller Sabrina³,Welch Verna⁴,Vandendries Erik⁵,Loberiza Fausto R.⁶,Böhme Sarah⁷,Su Yun⁸,Stelljes Matthias⁹,Kantarjian Hagop M.¹⁰^ORCID

Affiliation:

1. Bristol Haematology and Oncology Centre University Hospitals Bristol NHS Foundation Trust Bristol UK

2. Ingress‐Health Nederland B.V. Rotterdam The Netherlands

3. Ingress‐Health HWM GmbH Wismar Germany

4. Pfizer Global HEOR New York NY USA

5. Pfizer Inc Cambridge MA USA

6. Pfizer Inc, Pharma GmbH Berlin Germany

7. Pfizer Deutschland GmbH Berlin Germany

8. Independent Bridgewater NJ USA

9. Universitätsklinikum Münster Münster Germany

10. University of Texas MD Anderson Cancer Center Houston TX USA

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2480

Reference27 articles.

1. Cancer statistics, 2015

2. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

3. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

4. TREATMENT OF ADULT ALL ACCORDING TO PROTOCOLS OF THE GERMAN MULTICENTER STUDY GROUP FOR ADULT ALL (GMALL)

5. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients;Current Treatment Options in Oncology;2024-06-25

2. Recommendations for the treatment and management of adult B‐Cell acute lymphoblastic leukemia in Asia‐Pacific: Outcomes from a pilot initiative;Asia-Pacific Journal of Clinical Oncology;2023-12-26

3. Evaluation of the inpatient use of inotuzumab ozogamicin and creation of appropriate use guidelines;Journal of Oncology Pharmacy Practice;2023-07-18

4. The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review;JMIR Cancer;2023-05-01

5. Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia;American Journal of Hematology;2023-02-06